Bremen

• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit … Ended recruitment
  2024-511209-49-00 6 2022-04-26 Patients with hormone receptor positive HER2 negative locally advanced
• Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended recruitment
  2024-514473-21-00 5 2021-06-21 Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous s
• A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juven … Ended recruitment
  2023-507184-19-00 5 2021-02-22 Juvenile Psoriatic Arthritis  Enthesitis Related Arthritis
• Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended recruitment
  2024-511929-60-00 4 2021-01-28 Waldenström’s Macroglobulinemia
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo … Ended recruitment
  2024-518077-34-00 5 2020-09-30 locally advanced rectal cancer
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• The TARGET BP I Ended recruitment
  2024-512525-83-00 5 2020-01-07 Hypertension
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended recruitment
  2022-500584-12-00 4 2019-09-11 Waldenström’s Macroglobulinemia
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge
• Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours Ended recruitment
  2023-507582-25-00 5 2019-08-02 Malignant Extracranial Germ Cell Tumours (MGCT)
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Ended recruitment
  2024-515769-32-00 5 2019-07-02 HR+/HER2- early breast cancer
• Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio … Ended recruitment
  2022-502832-37-00 5 2019-03-01 Acute myeloid leukemia
• Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel … Ended recruitment
  2024-515783-31-00 5 2018-08-24 Newly Diagnosed Multiple Myeloma
• International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended recruitment
  2024-513070-21-00 4 2018-02-15 Relapsed Acute Lymphoblastic Leukemia (ALL)
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended recruitment
  2024-515499-12-00 5 2017-10-02 Acute lymphoblastic leukemia
• B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and … Ended recruitment
  2023-505509-18-00 5 2017-07-12 mature aggressive B-cell lymphoma and leukemia in children and adolesc
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404 … Halted
  2023-505096-68-00 4 2025-01-14 Preclinical Alzheimer’s Disease
• To investigate PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated re-lapsed/refractory AML or MDS/AML pa … Halted
  2024-514051-15-00 7 2023-07-10 Adult patients with relapsed or refractory IDH1-mutated AML or relapse

Showing 73–96 of 110 trials